William T. Abraham, M.D., F.A.C.P., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.E. Professor of Internal Medicine, Physiology and Cell Biology College of Medicine Distinguished Professor The Ohio State University Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado. He previously held leadership positions at the University of Colorado, the University of Cincinnati, the University of Kentucky, and The Ohio State University. At Ohio State, Dr. Abraham held several leadership positions including an Associate Dean position. As Director of the Clinical Trials Management Organization, Dr. Abraham managed the College of Medicine’s non-cancer clinical and translational research portfolio of more than 1,800 studies. As Division Director, Dr. Abraham developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S. Clinically, Dr. Abraham is board certified in Internal Medicine and Advanced Heart Failure and Transplant Cardiology. He spends most of his clinical time managing acute and chronic heart failure patients. Dr. Abraham has been recognized as one of the “Best Doctors in America” for twenty consecutive years and is ranked among the top 10% of physicians nationally for patient satisfaction. Dr. Abraham’s research activities focus on elucidating basic mechanisms in heart failure and on clinical drug and device development in heart failure. Dr. Abraham has received grants from the National Institutes of Health (NIH) including more than $11 million in NIH funding over the past five years, the American College of Cardiology, and the Aetna Quality Care Foundation. He has made major contributions to advancing basic and clinical science in heart failure in several areas including neurohormonal mechanisms, cardiorenal interactions, and the relationship between sleep and heart failure. Dr. Abraham has participated in all clinical and regulatory phases of new drug and device development for heart failure, frequently as national or international principal investigator for Phase 1 through Phase 3 trials. His work has led to the approval and adoption of several new therapies for heart failure, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, non-invasive and implantable hemodynamic monitoring systems, transvenous phrenic nerve stimulation, cardiac contractility modulation, transcatheter mitral valve repair, and baroreflex activation therapy. Dr. Abraham has authored more than 1,500 original papers, abstracts, book chapters, and review articles. His work has been published in high impact journals, including The New England Journal of Medicine, The Lancet, the Journal of the American Medical Association, Circulation, the European Heart Journal, and the Journal of the American College of Cardiology. Dr. Abraham serves on the editorial boards of several major journals. He has been named to the Clarivate Analytics (formerly Thomson Reuters) Highly Cited Researchers list and as one of The World’s Most Influential Scientific Minds. In 2017, he received the Distinguished Scientist Award from the American College of Cardiology, in recognition of his contributions to advancing cardiovascular medicine. In 2022, Dr. Abraham received the Pioneer Award from the Heart Failure Society of America, given to an innovator in the field of heart failure.